Skip to Content
Translational Research Program (TRP)
Contact CIP
Show menu
Search this site
Last Updated: 09/21/23

Cervical SPOREs

Cervical cancer development is driven by the transforming abilities of the human papillomavirus (HPV). Although the incidence of cervical cancer is fairly low in the United States due to the advent of the "pap" smear test and vaccination, 13,960 new cases and 4,310 deaths are projected in 2023 according to the NCI's Surveillance, Epidemiology, and End Results Program (SEER). The 5-Year relative survival rate is 67.2% (2013-2019). The Johns Hopkins University Cervical SPORE was first funded in 2013, and its major activities are focused on the development of the next generation of novel preventive and therapeutic vaccines to improve treatment outcomes of patients with HPV-associated cervical cancer and its precursor lesions.